The ETOP NICOLAS trial was first to demonstrate that it might be safe to simultaneously combine CRT and anti-PD-L1 antibodies in stage III NSCLC without an increased risk of pneumonitis (14). This evidence concerns the gene CD274 and non-small cell lung carcinoma.